Cargando…

Advance care planning in glioblastoma patients: development of a disease-specific ACP program

BACKGROUND: It is unknown if the implementation of an advance care planning (ACP) program is feasible in daily clinical practice for glioblastoma patients. We aimed to develop an ACP program and assess the preferred content, the best time to introduce such a program in the disease trajectory, and po...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritz, Lara, Zwinkels, Hanneke, Koekkoek, Johan A. F., Reijneveld, Jaap C., Vos, Maaike J., Dirven, Linda, Pasman, H. Roeline W., Taphoorn, Martin J. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989589/
https://www.ncbi.nlm.nih.gov/pubmed/31243585
http://dx.doi.org/10.1007/s00520-019-04916-9
_version_ 1783492434053824512
author Fritz, Lara
Zwinkels, Hanneke
Koekkoek, Johan A. F.
Reijneveld, Jaap C.
Vos, Maaike J.
Dirven, Linda
Pasman, H. Roeline W.
Taphoorn, Martin J. B.
author_facet Fritz, Lara
Zwinkels, Hanneke
Koekkoek, Johan A. F.
Reijneveld, Jaap C.
Vos, Maaike J.
Dirven, Linda
Pasman, H. Roeline W.
Taphoorn, Martin J. B.
author_sort Fritz, Lara
collection PubMed
description BACKGROUND: It is unknown if the implementation of an advance care planning (ACP) program is feasible in daily clinical practice for glioblastoma patients. We aimed to develop an ACP program and assess the preferred content, the best time to introduce such a program in the disease trajectory, and possible barriers and facilitators for participation and implementation. METHODS: A focus group with health care professionals (HCPs) and individual semi-structured interviews with patients and proxies (of both living and deceased patients) were conducted. RESULTS: All predefined topics were considered relevant by participants, including the current situation, worries/fears, (supportive) treatment options, and preferred place of care/death. Although HCPs and proxies of deceased patients indicated that the program should be implemented relatively early in the disease trajectory, patient-proxy dyads were more ambiguous. Several patient-proxy dyads indicated that the program should be initiated later in the disease trajectory. If introduced early, topics about the end of life should be postponed. A frequently mentioned barrier for participation was that the program would be too confronting, while a facilitator was adequate access to information. CONCLUSION: This study resulted in an ACP program specifically for glioblastoma patients. Although participants agreed on the program content, the optimal timing of introducing such a program was a matter of debate. Our solution is to offer the program shortly after diagnosis but let patients and proxies decide which topics they want to discuss and when. The impact of the program on several patient- and care-related outcomes will be evaluated in the next step. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00520-019-04916-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6989589
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-69895892020-02-11 Advance care planning in glioblastoma patients: development of a disease-specific ACP program Fritz, Lara Zwinkels, Hanneke Koekkoek, Johan A. F. Reijneveld, Jaap C. Vos, Maaike J. Dirven, Linda Pasman, H. Roeline W. Taphoorn, Martin J. B. Support Care Cancer Original Article BACKGROUND: It is unknown if the implementation of an advance care planning (ACP) program is feasible in daily clinical practice for glioblastoma patients. We aimed to develop an ACP program and assess the preferred content, the best time to introduce such a program in the disease trajectory, and possible barriers and facilitators for participation and implementation. METHODS: A focus group with health care professionals (HCPs) and individual semi-structured interviews with patients and proxies (of both living and deceased patients) were conducted. RESULTS: All predefined topics were considered relevant by participants, including the current situation, worries/fears, (supportive) treatment options, and preferred place of care/death. Although HCPs and proxies of deceased patients indicated that the program should be implemented relatively early in the disease trajectory, patient-proxy dyads were more ambiguous. Several patient-proxy dyads indicated that the program should be initiated later in the disease trajectory. If introduced early, topics about the end of life should be postponed. A frequently mentioned barrier for participation was that the program would be too confronting, while a facilitator was adequate access to information. CONCLUSION: This study resulted in an ACP program specifically for glioblastoma patients. Although participants agreed on the program content, the optimal timing of introducing such a program was a matter of debate. Our solution is to offer the program shortly after diagnosis but let patients and proxies decide which topics they want to discuss and when. The impact of the program on several patient- and care-related outcomes will be evaluated in the next step. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00520-019-04916-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-06-26 2020 /pmc/articles/PMC6989589/ /pubmed/31243585 http://dx.doi.org/10.1007/s00520-019-04916-9 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Fritz, Lara
Zwinkels, Hanneke
Koekkoek, Johan A. F.
Reijneveld, Jaap C.
Vos, Maaike J.
Dirven, Linda
Pasman, H. Roeline W.
Taphoorn, Martin J. B.
Advance care planning in glioblastoma patients: development of a disease-specific ACP program
title Advance care planning in glioblastoma patients: development of a disease-specific ACP program
title_full Advance care planning in glioblastoma patients: development of a disease-specific ACP program
title_fullStr Advance care planning in glioblastoma patients: development of a disease-specific ACP program
title_full_unstemmed Advance care planning in glioblastoma patients: development of a disease-specific ACP program
title_short Advance care planning in glioblastoma patients: development of a disease-specific ACP program
title_sort advance care planning in glioblastoma patients: development of a disease-specific acp program
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989589/
https://www.ncbi.nlm.nih.gov/pubmed/31243585
http://dx.doi.org/10.1007/s00520-019-04916-9
work_keys_str_mv AT fritzlara advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram
AT zwinkelshanneke advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram
AT koekkoekjohanaf advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram
AT reijneveldjaapc advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram
AT vosmaaikej advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram
AT dirvenlinda advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram
AT pasmanhroelinew advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram
AT taphoornmartinjb advancecareplanninginglioblastomapatientsdevelopmentofadiseasespecificacpprogram